ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
98,919.80
-5.49%
S&P 500
6,101.24
-0.29%
Dow Jones
44,424.25
-0.32%
US Dollar vs Yen
154.465
-0.98%
Brent Oil
77.805
0.80%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. NewAmsterdam Pharma Company NV (NAMSW)

  7. NewAmsterdam Pharma Company NV (NAMSW) ニュース

NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

NewAmsterdam Pharma Company NV
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NAMSW
日付受信時刻ニュースソース見出しコード企業名
2025/01/1106 : 26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/1022 : 27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/1022 : 00GlobeNewswire Inc.NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic PrioritiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/1005 : 38GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0907 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0807 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0807 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0807 : 15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0806 : 29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0707 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0707 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0707 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1407 : 16GlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1322 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1320 : 33Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1211 : 37GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1209 : 57Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1106 : 48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1106 : 34GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1106 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1021 : 24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1021 : 00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial HypercholesterolemiaNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/0706 : 01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/2021 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/2021 : 00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFHNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/1906 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/1905 : 20GlobeNewswire Inc.NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/1406 : 23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/0622 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/0622 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
 Showing the most relevant articles for your search:NASDAQ:NAMSW

最近閲覧した銘柄

NASDAQ
NVDA
NVIDIA
NYSE
CVX
Chevron
NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
NYSE
MRK
Merck
CCOM
US30
US 30
COIN
ADAUSD
Cardano
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
FX
USDEUR
US Dollar vs Euro
FX
USDJPY
US Dollar vs Yen
COIN
ETHUSD
Ethereum
CCOM
SILVER
SILVER
NYSE
VZ
Verizon Communications
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有